Eiger BioPharmaceuticals Inc
Change company Symbol lookup
Select an option...
EIGR Eiger BioPharmaceuticals Inc
ADBE Adobe Inc
GBTC Grayscale Bitcoin Trust (BTC)
GPN Global Payments Inc
BAC Bank of America Corp
BSRR Sierra Bancorp
MSI Motorola Solutions Inc
ESI Element Solutions Inc
INVZW Innoviz Technologies Equity Warrant Exp 05 April 2026 *W EXP 04/05/2026
BEN Franklin Resources Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development of therapies to treat and cure Hepatitis Delta Virus (HDV), the severe form of viral hepatitis, and other serious diseases. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Post-Bariatric Hypoglycemia (PBH) and Avexitide in Congenital Hyperinsulinism (CHI). Lambda is a late-stage, type III, interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. Avexitide is a peptide, which is developing as a treatment for congenital hyperinsulinism (HI). It is also developing lambda as an out-patient treatment for patients with mild and moderate COVID-19. The Company is also developing Avexitide as a treatment for post-bariatric hypoglycemia (PBH).

Price
Delayed
$3.93
Day's Change
-0.2099 (-5.07%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.12
Day's Low
3.93
Volume
(Below Average)

Today's volume of 150,548 shares is on pace to be lower than EIGR's 10-day average volume of 287,077 shares.

150,548
  • Prev Close
    4.14
  • Today's Open
    4.10
  • Day's Range
    3.93-4.12
  • Avg Vol (10-day)
    287.1K
  • Last (time)
    1:36p ET 12/06/22
  • Last (size)
    500
  • 52-Wk Range
    3.53 - 10.02
    LowHigh
  • (01/24/22 - 03/23/22)
    11.33%
  • 84.3%
  • Market Cap
    173.2M
  • Shares Outstanding
    44.1M
  • -2.41
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 1.4
  • 69.15
  • (% of float 11/15/22)
    3.99

Latest News

December 06, 2022
10:35 am ET
Newsfile
9:06 am ET
Newsfile
5:45 am ET
PR Newswire
December 05, 2022
4:32 pm ET
Accesswire
1:01 pm ET
Accesswire
12:38 pm ET
Globe Newswire
12:33 pm ET
Accesswire
11:00 am ET
Accesswire
10:00 am ET
Newsfile
8:30 am ET
Newsfile
8:16 am ET
Globe Newswire
5:45 am ET
PR Newswire
12:31 am ET
PR Newswire
December 03, 2022
5:45 pm ET
Accesswire
December 02, 2022
10:56 pm ET
PR Newswire
3:30 pm ET
Accesswire
2:46 pm ET
Newsfile
1:00 pm ET
PR Newswire
10:30 am ET
Accesswire
10:18 am ET
Newsfile
10:00 am ET
Globe Newswire
5:45 am ET
PR Newswire
December 01, 2022
8:00 pm ET
Accesswire
11:35 am ET
Globe Newswire
11:00 am ET
Globe Newswire
10:16 am ET
Newsfile
5:45 am ET
PR Newswire
November 30, 2022
4:13 pm ET
Newsfile
4:01 pm ET
Accesswire
2:17 pm ET
Newsfile
1:00 pm ET
Globe Newswire
12:17 pm ET
Globe Newswire
11:05 am ET
Accesswire
10:45 am ET
Accesswire
10:11 am ET
Newsfile
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.